Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This mechanistic trial compared the pharmacodynamics and safety of lixisenatide and liraglutide in combination with optimized insulin glargine with/without metformin in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration. The primary end point was change from baseline to week 8 in incremental area under the postprandial plasma glucose curve for 4 h after a standardized solid breakfast (AUC PPG0030–0430 h). Changes from baseline in gastric emptying, 24-h plasma glucose profile, HbA1c, fasting plasma glucose (FPG), 24-h ambulatory heart rate and blood pressure, amylase and lipase levels, and adverse events (AEs) were also assessed. RESULTS: In total, 142 patients were randomized and treated. Lixisenatide 20 µg achieved greater reductions of AUC PPG0030−0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, −6.0 [−7.8] h ⋅ mmol/L [−108.3 (−140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and −4.6 [−6.3] h ⋅ mmol/L [−83.0 (−114.2) h ⋅ mg/dL] vs. liraglutide 1.8 mg; P < 0.001 for both), and gastric emptying was delayed to a greater extent than with liraglutide 1.2 and 1.8 mg (P < 0.001 for treatment comparisons). FPG was unchanged in all treatment arms. At week 8, mean ± SD HbA1c was 6.2 ± 0.4% (44 ± 5 mmol/mol), 6.1 ± 0.3% (44 ± 4 mmol/mol), and 6.1 ± 0.3% (44 ± 4 mmol/mol) for lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg, respectively. At week 8, both liraglutide doses increased marginal mean ± SE 24-h heart rate from baseline by 9 ± 1 bpm vs. 3 ± 1 bpm with lixisenatide (P < 0.001). Occurrence of symptomatic hypoglycemia was higher with lixisenatide; gastrointestinal AEs were more common with liraglutide. Lipase levels were significantly increased from baseline with liraglutide 1.2 and 1.8 mg (marginal mean ± SE increase 21 ± 7 IU/L for both; P < 0.05). CONCLUSIONS: Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [51]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Cited by
Items 201–282 of 282
Moreno-Fernández, J., García-Seco, J. A., Seco, A. M., García-Seco, F., Rozas, P., & Sánchez-Covisa, M. A. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.05.006 · Cited by 8
Thong, K. Y., McGowan, B. M., Htay, T., Pernet, A., Kelly, C., Rajeswaran, C., Howell, J., Duncan, C., Inkster, B., Buchanan, L., et al. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.046 · Cited by 8
Another milestone in the evolution of GLP-1-based diabetes therapies
Nauck, M. A., Quast, D. R., & Meier, J. J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01394-7 · Cited by 7
Self-citationGlucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Zisman, A., DEX, T. A., Roberts, M., Saremi, A., Chao, J., & Aroda, V. R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0507-0 · Cited by 7
Darmon, P., & Raccah, D. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30005-2 · Cited by 7
Meier, J. J. (2016) · Der Internist · doi:10.1007/s00108-015-0002-x · Cited by 7
Self-citationBolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
Jalleh, R. J., Wu, T., Umapathysivam, M. M., Young, R. L., Jones, K. L., Marathe, C. S., Rayner, C. K., Plummer, M. P., & Horowitz, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00009.2025 · Cited by 6
Frías, J. P., Lorenz, M., Roberts, M., DEX, T. A., Schmider, W., Hurst, W., & SKOLNIK, N. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541316 · Cited by 6
Yamada, Y., Senda, M., Naito, Y., Tamura, M., Watanabe, D., Shuto, Y., & Urita, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12945 · Cited by 6
Htike, Z. Z., Zaccardi, F., Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.091 · Cited by 6
Monnier, L., Colette, C., & Owens, D. R. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30058-0 · Cited by 6
DAILEY, G. E., DEX, T. A., Roberts, M., Liu, M., & Meneilly, G. S. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12952 · Cited by 6
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Åhrén, B., Galstyan, G. R., Gautier, J., Giorgino, F., Peralta, F. G., Krebs, M., Nikonova, E., Stager, W., & Vargas‐Uricoechea, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0179-6 · Cited by 5
Monnier, L., Halimi, S., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30007-5 · Cited by 5
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Santos‐Pardo, I. (2024) · Open Archive (Karolinska Institutet) · Cited by 5
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
de Laat, M. A., Fitzgerald, D. M., Harris, P. A., & Bailey, S. R. (2023) · Journal of Animal Science · doi:10.1093/jas/skad389 · Cited by 4
Yin, J., Han, M., Li, L., Li, Y., Liu, Z., Yang, J., & Liu, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s331833 · Cited by 4
Chan, W. B., Luk, A. O. Y., Chow, W. S., & Yeung, M. W. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12515 · Cited by 4
Katagiri, N., Kigawa, I., Yahara, Y., Ueda, Y., Hamano, K., & Kaneko, S. (2016) · International Journal of Diabetes & Clinical Diagnosis · doi:10.15344/2394-1499/2016/117 · Cited by 4
Rayner, C. K., Jones, K. L., & Horowitz, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818586-5.00018-1 · Cited by 4
Besci, Ö., Güler, M. Ç., Foss‐Freitas, M. C., & Oral, E. A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2574318 · Cited by 3
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Sgarra, L., Matteucci, A., Monaco, A. D., Potenza, M. A., Desantis, V., Nacci, C., Noviello, C., Troisi, F., Caccavo, V. P., Mangini, F., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-67548-0 · Cited by 3
Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes
Matthews, J. E., Reinhardt, R. R., & Carr, M. C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174565 · Cited by 3
Insulin degludec + liraglutide: a complementary combination
Stinkens, K., Peene, B., & Mathieu, C. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1217328 · Cited by 3
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
Alghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide
Zhou, W., Huang, B., & Liu, M. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.219142 · Cited by 3
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
Rosenstock, J. (2021) · Diabetes Care · doi:10.2337/dci21-0004 · Cited by 3
Self-citationTudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Narayanasamy, S., & Kalagara, H. K. P. (2024) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_609_24 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus
Forst, T. M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1206079 · Cited by 2
Self-citationAustrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study
Brath, H., Abrahamian, H., Karuza, T., Mihaljevic, R., & Pfohl, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0558-2 · Cited by 2
Goutchtat, R. (2023) · theses.fr (ABES) · doi:10.70675/66d9d405zfe66z4a55zb024z7e6f43675b2f · Cited by 2
Yang, W., Guo, X., Lauand, F., Li, L., Fang, H., Du, Q., & Kang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15414 · Cited by 1
GLP1 receptor analogues and perioperative management considerations: A narrative review
Lima, A. V., & Lopo, M. V. (2026) · Revista Española de Anestesiología y Reanimación (English Edition) · doi:10.1016/j.redare.2026.501985 · Cited by 1
DPP-4-Hemmer und GLP-1-Rezeptor-Agonisten: Kardiovaskuläre Effekte
Nauck, M. A., Aziz, M. S. A. E., & Meier, J. J. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0083-8 · Cited by 1
Self-citationRoca-Rodríguez, M. D. M., Tapia, M. J., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.07.003 · Cited by 1
Roca-Rodríguez, M. D. M., Tapia, M. J., Maraver-Selfa, S., Tinahones, F. J., & Mancha-Doblas, I. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.07.004 · Cited by 1
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Alhamedi, N. M. (2025) · Journal of Clinical Medical Research · doi:10.46889/jcmr.2025.6104 · Cited by 1
Hemodynamic effects by glucagon-like peptide-1 receptor analogues: what should be measured?
Nilsson, P. M. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001315 · Cited by 1
Absorptive capacity of the OPEC countries
Newman, J., & McCowan, A. (1975) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 1
Gewichtssenkende Medikamente in der Diabetologie
Aberle, J. (2015) · Der Diabetologe · doi:10.1007/s11428-015-0004-2
Diabète de type2: échec de l'insulinothérapie basale
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00014-6
Heni, M., & Kempe-Teufel, D. S. (2017) · e Curriculum Innere Medizin · doi:10.1007/s40531-017-0017-z
Biomarkers associated with glycaemic control, comorbidity and response to GLP-1 analogue therapy
English, A. R. (2018) · Ulster University Research Portal (Ulster University)
Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review
Wongjarupong, N., Al-Hameed, M., Suchartikitwong, S., Assavapongpaiboon, B., & Salehian, B. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1076
Strategies for prandial intensification of insulin therapy: the SPRINT project
Corrao, S. (2017) · The Journal of AMD · doi:10.36171/jamd17.20.2.05
GLP-1 receptor agonists: evolution and advancement in the treatment of type 2 diabetes mellitus
Candido, R. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.2.4
Razera, A., Ivanski, F., Fermino, B. L., Santos, J. R., Horst, J. A. E., & de Campos, D. (2022) · Editora Pasteur eBooks · doi:10.29327/556278.1-8
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Monnier, L., & Halimi, S. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00029-4
Nielsen, T. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588597746
Demidova, T. Y., Titova, V. V., & Izmaylova, M. Y. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202425
Il ruolo dello svuotamento gastrico nell’omeostasi e nella controregolazione glucidica
Scientifica, D., Squatrito, S., Direttore, C., & Melloni, R. S. (2024) · il Diabete · doi:10.30682/ildia2304b
Incretins in healthy and type 2 diabetic people
Goglia, U. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.2.3
GLP-1 agonists in anaesthetic practice - a review of clinical data and recommendations
Pokrywka, N., Polak, M., Suwała, D., Hetnar, P., Fortuna, M., Kiper, S., Toczek, S., Tomala, M., Jastrowicz-Chęć, K., & Koryszko, K. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.83.61812
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Análogos del receptor GLP1 y consideraciones en el manejo perioperatorio: una revisión narrativa
Lima, A. V., & Lopo, M. V. (2025) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2025.501985
Cardiovascular Effects of GLP-1 and Glucagon Dual Receptor Agonism in Humans
Goodman, J. (2024) · Apollo (University of Cambridge) · doi:10.17863/cam.117744
Aziz, M. S. A. E. (2019) · Dokumentenrepositorium der RUB (Ruhr University Bochum) · doi:10.13154/294-6304
Quast, D. R. (2021) · Dokumentenrepositorium der RUB (Ruhr University Bochum) · doi:10.13154/294-8110
Bettge, K. (2018) · Dokumentenrepositorium der RUB (Ruhr University Bochum)
Yau, K. Y. T. (2025) · TSpace (University of Toronto)
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
Kwok, W. C., Zhou, L., Fung, T., Leung, R. Y. H., Tam, T. C. C., & Ho, J. (2026) · Journal of Asthma and Allergy · doi:10.2147/jaa.s622748
Khan, T. S. (2026) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2026.4152
Vlaeminck, N., & Saldien, V. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.07.075
Insights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity
Elashi, A. A., Hedaya, L., Maggio, V., Naja, K., Rizzo, M., & Elrayess, M. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1812193
Is Liraglutide a Safe and Effective Medication to Treat Hyperglycaemia?: A Systematic Review
Oneze, A. A., Jiwan, S. I., Gyasi-Antw, P., Meal, A., & Adams, G. G. (2020) · Repository@Nottingham (University of Nottingham)
Tavares, S. M. O. M. M. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Gestion des nouveaux traitements anti-diabétiques et anti-obésité
Besch, G., Ferreira, D., Berthier, F., Pili‐Floury, S., & Bronnert, R. (2026) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2026.08.001
Metadata
- Authors
- Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C.
- Affiliations
- St. Josef-Hospital (DE)
- Medical City Dallas Hospital (US)
- Sanofi (France) (FR)
- Profil Institute for Metabolic Research (DE)
- Profil, Mainz, Germany
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-17
- Volume
- 38
- Issue
- 7
- Pages
- 1263-1273
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2103274121
- Cited by
- 262
- References
- 50
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 21 · 2023: 18 · 2022: 7 · 2021: 18 · 2020: 23 · 2019: 26 · 2018: 27 · 2017: 38 · 2016: 39 · 2015: 17
- FWCI
- 34.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, liraglutide, type 2 diabetes, insulin glargine, metformin, postprandial glucose control, gastric emptying, incretin-based therapy, pharmacodynamics, HbA1c, fasting blood glucose, heart rate, blood pressure, amylase and lipase, drug safety, combination therapy, pharmacokinetics
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Insulin Glargine, Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Gastric Emptying, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Treatment Outcome, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.